Authors
Latest:
US Businesses Are Here to Help the Trump Administration Keep its Pledge to End HIVA coalition of over 100 US companies is supporting the federal initiative to end the HIV epidemic by 2030, but legal and funding threats now jeopardize this progress and the significant health and economic benefits it promises.
Latest:
Black Women and HIV: Breaking Down Barriers, Having Conversations in the CommunitiesThere are high infection rates in this population, but limited opportunities to bring about awareness and education. However, a newer program sponsored by ViiV Healthcare looks to engage these women and bring about a better understanding behind transmission and care.
Latest:
A New Approach to Treatment-Resistant C difficile InfectionFecal microbiota transplant (FMT) is a promising option for patients struggling with CDI recurrences. But how can we ensure the treatment is successful?
Latest:
What’s New With Non–COVID-19 VaccinesAlthough COVID-19 vaccination remains the primary focus for health care, other paramount vaccines need to be recognized. Here is a review.
Latest:
What Is a Better Treatment Approach for Immunocompromised Hosts With Clostridioides difficile Infection?Here is a review of the effectiveness of fidaxomicin vs vancomycin for CDI treatment in populations with immunocompromised conditions.
Latest:
Streptococcus Pneumoniae Bacteremia Secondary to Community-Acquired Pneumonia: Another Case of Shorter Is Better?Study questions whether reducing antibiotic treatment duration for pneumococcal bacteremia still ensures effective outcomes and minimizes risks.
Latest:
Model-Based Analysis of mRNA COVID-19 Vaccination Effectiveness in Washington and OregonMia Moore, PhD, presents findings showing 74% reduction in hospitalizations and key insights into primary vaccination and booster impact on population immunity in Washington and Oregon.
Latest:
Bad Bugs, New Drugs: A Discussion of Selected New Therapeutics From IDWeek 2022Cefepimetaniborbactam may represent a safe and effective carbapenemsparing agent in cUTI and AP, whereas ridinilazole may play an important role in treating CDI.
Latest:
Sorry Ganciclovir, You’re Just Not the One for MeImportant clinical considerations to know about resistant CMV infections.
Latest:
HIV and Mpox: Risks, Prevention, and Vaccine AccessIn the current state of the mpox outbreak, individuals with advanced HIV face a higher risk of severe illness, making vaccination and targeted public health measures essential.
Latest:
Key Takeaways on FMTs in the Treatment of CDIExperts provide practice pearls for educating patients on and using FMTs for the management of CDI.
Latest:
Invasive Nontyphoidal Salmonellosis: An Antimicrobial-Resistant FoeSalmonella becomes more dangerous as antimicrobial resistance grows. Read about its most common manifestations.
Latest:
Mixed Fungal Brain AbscessClinicians review a patient case including diagnosis, treatment, and follow-up.
Latest:
Improving Screening, Management of Hepatitis C in Infants and ChildrenDespite hepatitis C (HCV) incidence rates increasing, adequate screening for the virus continues to be a pressing challenge for public health officials.
Latest:
Undermining HIV Prevention Now Will Cost Billions LaterThe 15th anniversary of the Affordable Care Act is overshadowed by threats to HIV prevention efforts, including a looming Supreme Court case that could eliminate no-cost access to preexposure prophylaxis and other preventive services. Simultaneously, deep federal cuts and restructuring have destabilized critical public health infrastructure, jeopardizing decades of progress in the fight against HIV.
Latest:
From Poultry to Public Health: Understanding the H5N1 ThreatVeterinary and public health officials share the important roles of surveillance and prevention strategies, insights on the virus's transmission pathways, historical context, the One Health approach, and highlights effective precautionary measures to mitigate H5N1 risks.
Latest:
Going Viral on Social Media: Integrating Digital Tools into Pharmacy RotationsIn the latest Bench to Bedside column, 2 clinicians discuss the benefits of utilizing social media for learning.
Latest:
Merck’s Clesrovimab (Enflonsia) Receives FDA Approval to Protect Infants From RSV During First SeasonEnflonsia, a single-dose, long-acting antibody, has been FDA approved to significantly reduce RSV infections and hospitalizations in infants, providing new hope for protecting vulnerable babies during RSV season.
Latest:
The Future and Resources in HCV CareExpert hepatologists discuss future developments in HCV that they are excited about and provide resources for new providers to get started on delivering HCV care.
Latest:
Reducing Peripheral Venous Catheter InfectionsLack of data may mean bloodstream infections caused by PVCs are an overlooked cause of morbidity in hospitalized patients.
Latest:
Multidisciplinary Perspectives on HIV TreatmentA multidisciplinary panel concludes a discussion on best practices for managing patients with HIV in various healthcare settings and overcoming social health disparities.
Latest:
Rising Dengue Fever Cases Carry One Health ImplicationsThe increase highlights the threat posed by climate change and the need for innovative preparedness, prevention, and mitigation tools.
Latest:
The Yin and Yang of Ceftolozane-Tazobactam Resistance Against Multidrug-Resistant Pseudomonas aeruginosaRates of hospital-onset multidrug-resistant P aeruginosa infections have increased significantly in recent years.
Latest:
Considering the Value of Antiviral Resistance Testing in Certain PopulationsAt ASM Microbe 2025, Meghan Starolis, PhD, discusses her presentation on antiviral testing including the advantages and limitations to genotypic and phenotypic testing and looking at how this can affect the immunocompromised population.
Latest:
The Changing Climate of Vector-Borne DiseasesThese types of infections will continue to rise, and there is a need to understand what we are witnessing and find ways to combat them.
Latest:
Reduced-Dose Trimethoprim-Sulfamethoxazole Effective in Treating Mild to Moderate Pneumocystis jirovecii PneumoniaHere is a review of using this therapy in this patient population.
Latest:
What’s New in 2023 From the CLSI Subcommittee on Antimicrobial Susceptibility TestingThis year's Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing provided updated breakpoints on therapies.
Latest:
Long-Acting Injectables for the Prevention or Treatment of HIVIn the third installment of our series on injectables, long-acting injectables offer new treatment and prevention options for HIV, especially benefiting patients who struggle with daily oral medications.
Latest:
Where Do We Draw the Line? Duration of Antibiotic Therapy Varies for Bloodstream InfectionsWith potential delays in treatment, bloodstream infections can be concerning for clinicians. Here is a review of the literature that offer guidance for treatment.
